ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2025
A simulation study comparing anticholinergic drug use with polypharmacy for risk of death, dementia, and delirium in UK Biobank.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPolypharmacy and use of anticholinergics are associated with adverse health outcomes. Because these 2 exposures covary, it is not known to what extent the detrimental health effects attributed to anticholinergic burden measured by anticholinergic burden scales (ABS) may be due to polypharmacy.
methodsOur aims were to evaluate the added effect beyond polypharmacy of (1) anticholinergic use and (2) scores according to existing ABS. We used linked data from the UK Biobank prospective cohort study to investigate drugs prescribed in primary care in the year 2015 (n = ∼200 000; median age = 65 years). We randomly sampled among drugs to create 2000 pseudoscales-drug burden scales designed to reflect the strength of the background effect of polypharmacy. We differentiated pseudoscales constructed to capture either general polypharmacy or putative anticholinergic polypharmacy. For each scale, we fitted logistic regression adjusted for confounders to assess associations between pseudoscales from each set and risk of death, dementia, or delirium. We also assessed 23 existing ABS by comparing them to the effects of pseudoscales that included the same numbers of drugs as each ABS.
resultsOdds ratios for death, dementia, and delirium using anticholinergic-polypharmacy pseudoscales (median = 1.09-1.10) were greater than those of general-polypharmacy pseudoscales (1.05-1.06). The added effect of anticholinergic use beyond polypharmacy was greater in adjusted models and when prescribed to participants when they were older. 35%-90% of ABS exhibited stronger effects than most pseudoscales.
conclusionsThe models show an anticholinergic effect of drugs beyond polypharmacy or drug count, but it is small, ABS-dependent, and varies between outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.